Hydroxychloroquine for preexposure prophylaxis for SARS-CoV-2 https://doi.org/10.1101/2020.08.31.20185314 This is a retrospective cohort study. The exposed cohort was formed by individuals with autoimmune diseases with HCQ treatment. The control cohort was randomly selected using the Health Card database. To deal with… Continue reading "(02 Sep 2020) Hydroxychloroquine- did not offer preexposure prophylaxis"
Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness https://doi.org/10.1101/2020.08.31.20182428 A total of 1,092 COVID-19 patients were admitted during the study period. Of them, 186 (17%) were treated with TCZ, of which 129… Continue reading "(01 Sep 2020) Corticosteroids and Tocilizumab- combination therapy protective against in-hospital mortality"
Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial https://doi.org/10.1016/j.intimp.2020.106903 In this study (IRCT20100228003449N27), efficacy and safety of interferon (IFN) beta-1b in the treatment of patients with severe COVID-19 were evaluated. The primary outcome of the study was… Continue reading "(31 Aug 2020) Interferons- IFN β-1b significantly increased the discharge rate at day 14"
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) https://doi.org/10.1016/j.cmi.2020.08.010 A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 with clinical and laboratory data indicative of hyperinflammatory state.… Continue reading "(30 Aug 2020) Tocilizumab- associated with lower hazard of death"
Tocilizumab use in COVID -19 associated pneumonia https://doi.org/10.1002/jmv.26471 Out of 77 patients who received TCB in addition to standard of care, 34% (n=26) received TCB within 48 hours of admission. One-to-two propensity matching identified 20 vs. 40 patients in the… Continue reading "(30 August 2020) Tocilizumab- improvement in oxygenation was observed in 80% (n=16) of the patients by7 days"
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study https://doi.org/10.1016/j.ejim.2020.08.019 In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy. Out of 3,451 COVID-19… Continue reading "(30 Aug 2020) Hydroxychloroquine- associated with a 30% lower risk of death in COVID-19 hospitalized patients"
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19 https://doi.org/10.14309/ajg.0000000000000832 Of 878 patients in the analysis, 83 (9.5%) received famotidine. In comparison to patients not treated with famotidine, patients treated with famotidine were younger (63.5 +/- 15.0… Continue reading "(28 Aug 2020) Famotidine- associated with a lower risk of mortality"
Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants https://doi.org/10.1016/j.ijantimicag.2020.106144 Of 8075 patients with complete discharge data on 24(th) of May and diagnosed before the 1(st) of May, 4542 received HCQ in… Continue reading "(28 Aug 2020) Hydroxychloroquine- low-dose HCQ monotherapy was independently associated with lower mortality in hospitalized patients"
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients https://doi.org/10.3389/fphar.2020.01124 The in-hospital mortality between COVID-19 patients treated with standard prophylactic LMWH dosage vs. intermediate LMWH dosage was compared in a retrospective study. Out of 450 patients, 361 received… Continue reading "(28 Aug 2020) LMW Heparin-associated with lower incidence of mortality"
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol https://doi.org/10.3389/fmed.2020.00466 Data collection shows a rapid clinical response with no evolution from non-invasive ventilation to mechanical ventilation in 16/18 patients and no response in… Continue reading "(28 Aug 2020) Ruxolinitib- after 48 h of ruxolitinib treatment 16/18 patients showed evident clinical improvement"
